{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:19:17Z","timestamp":1790795957209,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["CUP E65E24002260002"],"award-info":[{"award-number":["CUP E65E24002260002"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jns.2025.125681","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:28:20Z","timestamp":1764894500000},"page":"125681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis"],"prefix":"10.1016","volume":"480","author":[{"given":"Valerio","family":"Nicolella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Varelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Polito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Sirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"La Civita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Fiorenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Novarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jns.2025.125681_bb0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jns.2025.125681_bb0010","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/13524585211049392","article-title":"Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study","volume":"28","author":"Giovannoni","year":"2022","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jns.2025.125681_bb0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","article-title":"Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge","volume":"92","author":"Gasperini","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.125681_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41582-019-0268-z","article-title":"Immune reconstitution therapies: concepts for durable remission in multiple sclerosis","volume":"16","author":"L\u00fcnemann","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2025.125681_bb0025","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/brain\/awaf144","article-title":"Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination","volume":"148","author":"Abdelhak","year":"2025","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.jns.2025.125681_bb0030","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1007\/s00415-024-12434-w","article-title":"The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis","volume":"271","author":"Monteiro","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.125681_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ene.15588","article-title":"Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis","volume":"30","author":"Camara-Lemarroy","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2025.125681_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16323","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses","volume":"31","author":"Vardakas","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2025.125681_bb0045","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3390\/brainsci12121595","article-title":"Real-life experience of the effects of cladribine tablets on lymphocyte subsets and serum neurofilament light chain levels in relapsing multiple sclerosis patients","volume":"12","author":"Paolicelli","year":"2022","journal-title":"Brain Sci."},{"issue":"4","key":"10.1016\/j.jns.2025.125681_bb0050","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/ijms24044067","article-title":"Serum Neurofilament light chain as biomarker for cladribine-treated multiple sclerosis patients in a real-world setting","volume":"24","author":"Seiberl","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"462","key":"10.1016\/j.jns.2025.125681_bb0055","article-title":"Clinical and biological predictors of Cladribine effectiveness in multiple sclerosis: a real-world, single Centre study considering a two-year interval from year-2 dosing","author":"Manni","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2025.125681_bb0060","article-title":"Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study","volume":"3","author":"Wiendl","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.jns.2025.125681_bb0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00415-025-13223-9","article-title":"Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis","volume":"272","author":"Nicolella","year":"2025","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125681_bb0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"Pt 11","key":"10.1016\/j.jns.2025.125681_bb0075","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jns.2025.125681_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"Simr\u00e9n","year":"2022","journal-title":"Brain Commun."},{"issue":"1","key":"10.1016\/j.jns.2025.125681_bb0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acn3.51704","article-title":"Associations of sNfL with clinico-radiological measures in a large MS population","volume":"10","author":"Sotirchos","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2025.125681_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209357","article-title":"Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis","volume":"102","author":"Fox","year":"2024","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.jns.2025.125681_bb0095","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2025.125681_bb0100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.jns.2025.125681_bb0105","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light chain elevation and disability progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125681_bb0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis","volume":"11","author":"Abdelhak","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2025.125681_bb0115","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1093\/brain\/awae260","article-title":"Serum biomarkers at disease onset for personalized therapy in multiple sclerosis","volume":"147","author":"Monreal","year":"2024","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2025.125681_bb0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.27096","article-title":"Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-cell depleting treatment in multiple sclerosis","volume":"97","author":"Benkert","year":"2024","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2025.125681_bb0125","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jns.2025.125681_bb0130","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of Cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.jns.2025.125681_bb0135","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurol. Ther."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:33:34Z","timestamp":1777394014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25023019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"alternative-id":["S0022510X25023019"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.125681","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125681"}}